OMBA Runs FINBOURNE Agentic AI in Production Across Daily Investment Operations September 10, 2026 OMBA Advisory & Investments and FINBOURNE Technology today announced that OMBA has been running FINBOURNE agents in production for six months across its daily investment operations, reducing its operational burden by at least 20%. The agents provide coverage across a large portion of OMBA’s daily operational cycle from morning data load checks and reconciliations through [...]
New Circularity Data: Nine Out of Ten Returned Items Lose Value for Retailers September 10, 2026 New research finds 86% of retailers have established circularity practices, yet only 9% resell more than half of returned products at full price
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program September 10, 2026 — Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Narcolepsy and Idiopathic Hypersomnia in Addition to Schizophrenia and Bipolar I Disorder — — Stage One Submission Period Runs From Sept. 11, 2026 Through Oct. 16, 2026 —
Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines September 10, 2026 Investment will support Ride's Molecular Logistics™ platform with the goal of delivering genetic medicines to the lung for all people living with cystic fibrosis Ride’s platform is designed to learn the rules of delivery by tracking the destinations of millions of diverse carriers for genetic medicines in the body Billions of datapoints can be used to train a generative AI design engine and produce optimized carriers for any tissue or cell type of interest Investment is expected to both accelerate Ride’s existing progress using IV delivery and support expansion of the technology for inhaled delivery Ride was launched in 2023, funded by an US$8.0 million seed round
Transition Bio Partners with the Little Warrior Foundation September 10, 2026 Transition Bio receives $750,000 grant from the Little Warrior Foundation Mission: advance science in one of cancer’s most elusive targets - EWS-FLI1 Goal: create a therapeutic for an aggressive pediatric cancer – Ewing Sarcoma Leverage Transition Bio’s molecular drug discovery + protein science-based approach Enabled by Transition Bio’s proprietary physical science tools, data and machine learning
Trolley Research: Independent Earners Won’t Wait More Than Two Days to Get Paid, and Payment Problems Are Pushing Them Off Platforms September 10, 2026 A survey of 450 freelancers, creators, and musicians finds only 28% control when their money arrives, while payment delays now outrank a lack of work as a reason to leave
GasEntec Announces New Ownership Structure, Accelerating Next Phase of Global Growth September 10, 2026 Independent LNG infrastructure and technology company expands investment in proprietary technology, modular solutions and global project development.
EUMETSAT Takes Control of MTG-I2 September 10, 2026 EUMETSAT’s Mission Control Centre in Darmstadt, Germany, took over control of the newest addition to its fleet of meteorological satellites, Meteosat Third Generation Imager 2 (MTG-I2), on 9 September 2026, following the successful completion of its Launch and Early Orbit Phase (LEOP). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909889951/en/ MTG-I2 launched [...]
Capgemini: Life insurers under pressure: 42% of consumers are confused and unconvinced by policies September 10, 2026 Technical language (37%), affordability concerns (35%), and lack of relevance to life stage (25%) among top barriers to purchasing life insurance Half of consumers plan to use generative AI tools to discover and compare life insurance products Nearly 40% of policyholders rarely hear from their life insurer after purchasing a policy, while half of those who discontinue coverage do so within the first three years Best-in-class life insurers, representing 10% of the industry, achieve 41% higher revenue growth and 12% lower lapse rates by combining consumer-led strategies with intelligence-powered operations
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference September 9, 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026 at 8:30 a.m. ET in [...]
